SOURCE: Angle PLC

April 04, 2017 02:00 ET

Angle PLC Announces Holding(s) in Company

GUILDFORD, SURREY--(Marketwired - Apr 4, 2017) - Angle PLC (AIM: AGL) (OTCQX: ANPCY)

AIM: AGL; OTCQX: ANPCY

For immediate release   4 April 2017

ANGLE plc ("the Company")

Holding(s) in Company

The Company has been informed by Lombard Odier Investment Managers group ("Lombard") that, following its recent acquisition of Henderson Volantis from Henderson Global plc ("Henderson"), Lombard has acquired ordinary shares in the Company via an in-specie transfer of accounts managed by Henderson on a discretionary basis to Lombard. Further information is set out below. 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
     
  1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii      ANGLE Plc
  2 Reason for the notification (please tick the appropriate box or boxes):
  An acquisition or disposal of voting rights    
  An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached    
  An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments    
  An event changing the breakdown of voting rights    
  Other (please specify): Transfer of accounts managed on a discretionary basis by Henderson Group Plc to Lombard Odier Investment Managers group      X
  3. Full name of person(s) subject to the notification obligation: iii     Lombard Odier Asset Management (Europe) Limited
  4. Full name of shareholder(s)
 (if different from 3.):iv
    Disclosure on behalf of accounts managed on a discretionary basis by Lombard Odier Investment Managers group.
  5. Date of the transaction and date on
which the threshold is crossed or
reached:
v
    01/04/2017
  6. Date on which issuer notified:     03/04/2017
  7. Threshold(s) that is/are crossed or
reached:
vi, vii
     above 5%
 
8. Notified details:
A: Voting rights attached to sharesviii, ix
Class/type of
shares
if possible using
the ISIN CODE
Situation previous
to the triggering
transaction
  Resulting situation after the triggering transaction
Number
of
Shares
  Number
of
Voting
Rights
  Number
of shares
  Number of voting
rights
  % of voting rights x
Direct   Direct xi   Indirect xii   Direct   Indirect
GB0034330679                 5,899,164       7.88%
 
 
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrument
  Expiration
date
xiii
  Exercise/
Conversion Period
xiv
  Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
  % of voting
rights
                 
 
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial
instrument
Exercise price   Expiration date xvii   Exercise/
Conversion period
xviii
  Number of voting rights instrument refers to   % of voting rights xix, xx
                  Nominal   Delta
       
 
Total (A+B+C)
Number of voting rights   Percentage of voting rights
5,899,164   7.88%
                           
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi
 
 
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold
voting rights:
 

13. Additional information:
   
14. Contact name:   Kiran Bassi
15. Contact telephone number:   +44 20 3206 6000
     
  TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
     
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:ii   ANGLE Plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights    
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached    
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments    
An event changing the breakdown of voting rights    
Other (please specify): In specie transfer out   X
3. Full name of person(s) subject to the notification obligation:iii   Henderson Group plc
4. Full name of shareholder(s)
 (if different from 3.):iv
   
5. Date of the transaction and date on
which the threshold is crossed or
reached:
v
  31 March 2017
6. Date on which issuer notified:   3 April 2017
7. Threshold(s) that is/are crossed or
reached:
vi, vii
  Below 5%
 
8. Notified details:
A: Voting rights attached to sharesviii, ix
Class/type of
shares
if possible using
the ISIN CODE
  Situation previous
to the triggering
transaction
  Resulting situation after the triggering transaction
Number
of
Shares
  Number
of
Voting
Rights
  Number
of shares
  Number of voting
rights
  % of voting rights x
Direct   Direct xi   Indirect xii   Direct   Indirect
Ordinary   4,205,074   4,205,074           Below 5%       Below 5%
GB0034330679  
 
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrument
  Expiration
date
xiii
  Exercise/
Conversion Period
xiv
  Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
  % of voting
rights
                 
 
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial
instrument
  Exercise price   Expiration date xvii   Exercise/
Conversion period
xviii
  Number of voting rights instrument refers to   % of voting rights xix, xx
                    Nominal   Delta
     
 
Total (A+B+C)
Number of voting rights   Percentage of voting rights
Below 5%   Below 5%
                             
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi

 See Annex 1 below.
 
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
 

13. Additional information:
   
14. Contact name:   HGIThresholdDisclosures@henderson.com
15. Contact telephone number:   020 7818 1818
     
Annex 1: Information in relation to the person subject to the notification obligation (please tick the applicable box):[ ] Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.xiii[X] Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity
xiv:
Namexv   % of voting rights if it equals or is higher than the notifiable threshold   % of voting rights through financial instruments if it equals or is higher than the notifiable threshold   Total of both if it equals or is higher than the notifiable threshold
Henderson Group plc, Henderson Group Holdings Asset Management Limited, HGI Asset Management Group Limited, Henderson Global Group Limited, Henderson Holdings Group Limited, HGI Group Limited, Henderson Global Investors (Holdings) Limited, AlphaGen Capital Limited   Below 5%   -   Below 5%
             
Henderson Group plc, Henderson Group Holdings Asset Management Limited, HGI Asset Management Group Limited, Henderson Global Group Limited, Henderson Holdings Group Limited, HGI Group Limited, Henderson Global Investors (Holdings) Limited, Henderson Global Investors Limited   Below 5%   -   Below 5%

For further information:

ANGLE plc   01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
   
Cenkos Securities
Stephen Keys (Nominated adviser), Steve Cox
Russell Kerr (Sales)  
  020 7397 8900
WG Partners
David Wilson
Claes Spång
  020 3705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie Cuthbert
Kimberly Ha (US)  
 
020 3727 1000
001 212 850 5612

For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/

Notes for editors

About ANGLE plc  www.angleplc.com 
ANGLE is a specialist medtech company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.

ANGLE's cell separation technology is called the Parsortix™ system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. Parsortix has a CE Mark for Europe and FDA authorisation is in process for the United States. 

ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here http://www.angleplc.com/the-company/collaborators/

The analysis of the cells that can be harvested from patient blood with ANGLE's Parsortix system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.

The global increase in cancer to a 1 in 3 lifetime incidence is set to drive a multi-billion dollar clinical market. The Parsortix system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug's effectiveness.

As well as cancer, the Parsortix technology has the potential for deployment with several other important cell types in the future.

ANGLE stock trades on the AIM market of the London Stock Exchange under the ticker symbol AGL and in New York on the OTC-QX under the ticker symbol ANPCY. For further information please visit: www.angleplc.com

This information is provided by RNS
The company news service from the London Stock Exchange

Contact Information